UK-based Suncombe, a specialist in advanced bio-waste decontamination, clean-in-place (CIP) systems and high-purity process skids, has completed a landmark project with Kindeva.
The partnership supports the NHS’s Net Zero ambitions by enabling the development and production of low Global Warming Potential (GWP) pressurised metered-dose inhalers (pMDIs).
Inhaler propellants account for ~3% of the NHS’s total carbon footprint. Although traditional propellants are effective for asthma treatment, they also come with a significant environmental impact.
New low-GWP alternatives can reduce emissions by more than 90% compared with the currently used HFA-134a propellant.
Kindeva’s next generation of inhalers using these low-GWP pMDIs will allow for substantial environmental benefits while still continuing to provide vital therapies for patients.
For this project, Kindeva, one of the UK’s largest inhaler manufacturers, has made a significant investment in its Loughborough facility.
This expansion will enable large-scale production of inhalers using the new alternative propellants.
The collaboration leverages Suncombe’s decades of experience in designing solutions for high-purity and biopharma applications, delivering reliable performance while meeting the strict standards of the pharmaceutical sector.
Steve Overton, Suncombe’s Operations Director, said: “We have worked with the Loughborough site for many years producing equipment for their production lines and were honoured to be asked to be involved in this incredibly important project for Kindeva, for the NHS and ultimately for the sustainability of the world environment.”
Craig Sommerville, Senior Vice President of the MDI business unit at Kindeva, commented: “Establishing Loughborough as Kindeva’s MDI centre of excellence will transform the lives of patients across the world."
"Our partnership with Suncombe will continue to showcase our expertise as market leaders in the field and allow Kindeva to support the NHS with its transition to next-generation propellants, whilst treating patients with respiratory conditions.”
The partnership sets a benchmark in the industry in both innovation and responsibility, demonstrating how UK-based engineering and manufacturing expertise can play a vital role in addressing global challenges.